CONTEXT: Commercial announcement of a significant acquisition in the RWD space | Is this the biggest deal we will see this year or is there more to come?
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 8
1. “Kantar Health’s rich life sciences expertise will be combined with Cerner’s robust collection of real-world data (RWD) and technology and is expected to accelerate innovation in life sciences research and improve patient outcomes worldwide.”
2. “The growing Cerner Learning Health NetworkSM client consortium, which today represents 92 million patients and 776 million clinical encounters, will be able to engage more with life sciences companies for funded research studies.”
3. “As a result of the transaction closing, the Kantar Health team located around the world is joining Cerner and will be integrated within its Strategic Growth business.”
4. ““Kantar Health and Cerner’s Strategic Growth business have a great deal in common, starting with a vision to advance patient care around the world.”
5. “Factors that could cause or contribute to such differences include, but are not limited to: risks inherent with business acquisitions and integrations, such as difficulties and operational and financial risks associated with integrating Cerner and the acquired business generally and during the COVID-19 pandemic; the occurrence of any event, change or other circumstances that could make closing in a specific country impracticable; risks related to disruption of management time from ongoing business operations due to the transaction and integration; failure to realize the synergies, market opportunities and other benefits expected from the transaction; risk that the assets and business acquired may not continue to be commercially successful; the ability of Cerner and Kantar Health to retain customers and key personnel and to maintain relationships with key suppliers of the acquired business; unexpected costs, charges or expenses resulting from the transaction or the integration; litigation or claims relating to the transaction or the acquired assets and business; and the extent to which the COVID-19 pandemic and measures taken in response thereto could adversely affect the business acquired and the assumptions management has used in its evaluation of the transaction.”